Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10


Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models.

Hubaux R, Vandermeers F, Cosse JP, Crisanti C, Kapoor V, Albelda SM, Mascaux C, Delvenne P, Hubert P, Willems L.

ERJ Open Res. 2015 Oct 19;1(2). pii: 00028-2015. eCollection 2015 Oct.


The role of epigenetics in malignant pleural mesothelioma.

Vandermeers F, Neelature Sriramareddy S, Costa C, Hubaux R, Cosse JP, Willems L.

Lung Cancer. 2013 Sep;81(3):311-8. doi: 10.1016/j.lungcan.2013.05.014. Epub 2013 Jun 18. Review.


Chemoresistance to Valproate Treatment of Bovine Leukemia Virus-Infected Sheep; Identification of Improved HDAC Inhibitors.

Gillet N, Vandermeers F, de Brogniez A, Florins A, Nigro A, François C, Bouzar AB, Verlaeten O, Stern E, Lambert DM, Wouters J, Willems L.

Pathogens. 2012 Oct 8;1(2):65-82. doi: 10.3390/pathogens1020065.


Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.

Hubaux R, Vandermeers F, Crisanti MC, Kapoor V, Burny A, Mascaux C, Albelda SM, Willems L.

Eur J Cancer. 2010 Jun;46(9):1724-34. doi: 10.1016/j.ejca.2010.03.021. Epub 2010 May 5. Erratum in: Eur J Cancer. 2010 Nov;46(17):3127. Crisanti, Cecilia [corrected to Crisanti, M Cecilia].


The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer.

Crisanti MC, Wallace AF, Kapoor V, Vandermeers F, Dowling ML, Pereira LP, Coleman K, Campling BG, Fridlender ZG, Kao GD, Albelda SM.

Mol Cancer Ther. 2009 Aug;8(8):2221-31. doi: 10.1158/1535-7163.MCT-09-0138. Epub 2009 Aug 11.


Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.

Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A, Scherpereel A, Willems L.

Clin Cancer Res. 2009 Apr 15;15(8):2818-28. doi: 10.1158/1078-0432.CCR-08-1579. Epub 2009 Apr 7.


Emphasis on cell turnover in two hosts infected by bovine leukemia virus: a rationale for host susceptibility to disease.

Florins A, Boxus M, Vandermeers F, Verlaeten O, Bouzar AB, Defoiche J, Hubaux R, Burny A, Kettmann R, Willems L.

Vet Immunol Immunopathol. 2008 Sep 15;125(1-2):1-7. doi: 10.1016/j.vetimm.2008.04.007. Epub 2008 Apr 16. Review.


Mechanisms of leukemogenesis induced by bovine leukemia virus: prospects for novel anti-retroviral therapies in human.

Gillet N, Florins A, Boxus M, Burteau C, Nigro A, Vandermeers F, Balon H, Bouzar AB, Defoiche J, Burny A, Reichert M, Kettmann R, Willems L.

Retrovirology. 2007 Mar 16;4:18. Review.


Cell dynamics and immune response to BLV infection: a unifying model.

Florins A, Gillet N, Asquith B, Boxus M, Burteau C, Twizere JC, Urbain P, Vandermeers F, Debacq C, Sanchez-Alcaraz MT, Schwartz-Cornil I, Kerkhofs P, Jean G, Théwis A, Hay J, Mortreux F, Wattel E, Reichert M, Burny A, Kettmann R, Bangham C, Willems L.

Front Biosci. 2007 Jan 1;12:1520-31. Review.


Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo.

Achachi A, Florins A, Gillet N, Debacq C, Urbain P, Foutsop GM, Vandermeers F, Jasik A, Reichert M, Kerkhofs P, Lagneaux L, Burny A, Kettmann R, Willems L.

Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10309-14. Epub 2005 Jul 8.

Supplemental Content

Loading ...
Support Center